Literature DB >> 31004592

Postconcussion: Receded Near Point of Convergence is not Diagnostic of Convergence Insufficiency.

Aparna Raghuram1, Susan A Cotter2, Sowjanya Gowrisankaran3, Jameel Kanji4, David R Howell5, William P Meehan6, Ankoor S Shah7.   

Abstract

PURPOSE: To determine the frequency of occurrence of receded near point of convergence (NPC) in patients with chronic concussion-related symptoms and in those with receded NPC to enumerate the frequency of convergence insufficiency and other oculomotor disorders.
DESIGN: Retrospective cross-sectional study.
METHODS: Clinic charts were retrospectively reviewed for the prior 3.5 years to identify all patients < 21 years old who were > 28 days postconcussion, had chronic concussion-related symptoms, had normal visual acuity, and had received a comprehensive sensorimotor examination. The frequency of receded NPC and oculomotor diagnoses were determined.
RESULTS: Of the 83 eligible patients, 74 (89%) had receded NPC. Of these, 70 (95%) had oculomotor disorders; 30 (41%) had disorders of accommodation only; 21 (28%) had convergence insufficiency and accommodation deficits; and 6 (8%) had convergence insufficiency only. Six (8%) had a convergence deficit other than convergence insufficiency (all with concurrent accommodative disorders); 4 (5%) had both a nonspecific vergence dysfunction and accommodation deficits; 2 (3%) had convergence excess only; and 1 (1%) had both convergence excess and accommodative deficits.
CONCLUSION: A receded NPC was present in the majority of young patients with chronic postconcussion symptoms. Associated with numerous underlying oculomotor dysfunctions, the clinical finding of a receded NPC is not synonymous with the diagnosis of convergence insufficiency. Because treatment options for the various oculomotor dysfunctions differ, it is prudent that these patients undergo a thorough examination of their vergence and accommodative systems so that an accurate diagnosis can be made and appropriate treatment prescribed.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31004592     DOI: 10.1016/j.ajo.2019.04.008

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Utility of 1 Measurement Versus Multiple Measurements of Near Point of Convergence After Concussion.

Authors:  Nathan Ernst; Philip Schatz; Alicia M Trbovich; Kouros Emami; Shawn R Eagle; Anne Mucha; Michael W Collins; Anthony P Kontos
Journal:  J Athl Train       Date:  2020-08-01       Impact factor: 2.860

2.  Association between post-concussion symptoms and oculomotor deficits among adolescents.

Authors:  Sowjanya Gowrisankaran; Ankoor S Shah; Tawna L Roberts; Emily Wiecek; Ryan N Chinn; Karameh K Hawash; Michael J O'Brien; David R Howell; William P Meehan; Aparna Raghuram
Journal:  Brain Inj       Date:  2021-08-12       Impact factor: 2.167

3.  OculoMotor Assessment Tool: Children Compared with Adults.

Authors:  Rachel Eichler; Gila Mivtachi; Dina Hershkovitz-Azoulay; Mitchell Scheiman; Hadas Ben-Eli
Journal:  Clin Optom (Auckl)       Date:  2022-05-27

4.  Vergence, accommodation, and visual tracking in children and adolescents evaluated in a multidisciplinary concussion clinic.

Authors:  Emily K Wiecek; Tawna L Roberts; Ankoor S Shah; Aparna Raghuram
Journal:  Vision Res       Date:  2021-04-07       Impact factor: 1.984

5.  The Association between Baseline Eye Tracking Performance and Concussion Assessments in High School Football Players.

Authors:  Jessie R Oldham; Christina L Master; Gregory A Walker; William P Meehan; David R Howell
Journal:  Optom Vis Sci       Date:  2021-07-01       Impact factor: 2.106

6.  Disparity vergence differences between typically occurring and concussion-related convergence insufficiency pediatric patients.

Authors:  Tara L Alvarez; Chang Yaramothu; Mitchell Scheiman; Arlene Goodman; Susan A Cotter; Kristine Huang; Angela M Chen; Matthew Grady; Anne E Mozel; Olivia E Podolak; Chris G Koutures; Christina L Master
Journal:  Vision Res       Date:  2021-04-23       Impact factor: 1.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.